Top

Published in:

01-12-2017 | Original Contribution

Relationship between soluble receptor for advanced glycation end products (sRAGE), body composition and fat distribution in healthy women

Authors: Elena Dozio, Silvia Briganti, Alessandra Delnevo, Elena Vianello, Federica Ermetici, Francesco Secchi, Francesco Sardanelli, Lelio Morricone, Alexis E. Malavazos, Massimiliano M. Corsi Romanelli

Published in: European Journal of Nutrition | Issue 8/2017

Abstract

Purpose

Soluble receptor for advanced glycation end products (sRAGE) is a decoy receptor which sequesters RAGE ligands and acts as a cytoprotective agent. To date, it is unclear whether the lower sRAGE levels observed in obesity are a marker of increased overall adiposity or reflect increases in particular fat depots. Therefore, we evaluated in healthy women the relationship among sRAGE and indicators of adiposity, including abdominal visceral (VAT) and epicardial visceral (EAT) adipose tissues, to explore the potential role of sRAGE as an earlier biomarker of cardiometabolic risk.

Methods

Plasma sRAGE levels were quantified by an enzyme-linked immunosorbent assay in 47 healthy women. Total fat mass (FM) and fat-free mass were estimated with bioimpedance analysis. Anthropometric measures and biochemical data were recorded. Subcutaneous adipose tissue, VAT and EAT volumes were measured by magnetic resonance imaging.

Results

Obese women had lower sRAGE levels compared to normal-weight women. sRAGE levels were also lower in women with a waist circumference (WC) larger than 80 cm. Correlation analyses indicated an inverse association of sRAGE with body mass index and FM. Concerning adipose tissue distribution, sRAGE inversely correlated with WC, EAT and VAT depots. In a multiple stepwise regression analysis, performed to emphasize the role of fat distribution, EAT volume was the only predictor of sRAGE.

Conclusions

Lower sRAGE levels reflect accumulation of visceral fat mainly at the epicardial level and are present in advance of metabolic complications in adult women. sRAGE quantification might be an early marker of cardiometabolic risk.

Kislinger T, Fu C, Huber B, Qu W, Taguchi A, Du Yan S, Hofmann M, Yan SF, Pischetsrieder M, Stern D, Schmidt AM (1999) N(epsilon)-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J Biol Chem 274(44):31740–31749CrossRef

Malherbe P, Richards JG, Gaillard H, Thompson A, Diener C, Schuler A, Huber G (1999) cDNA cloning of a novel secreted isoform of the human receptor for advanced glycation end products and characterization of cells co-expressing cell-surface scavenger receptors and Swedish mutant amyloid precursor protein. Brain Res Mol Brain Res 71(2):159–170CrossRef

Hofmann MA, Drury S, Fu C, Qu W, Taguchi A, Lu Y, Avila C, Kambham N, Bierhaus A, Nawroth P, Neurath MF, Slattery T, Beach D, McClary J, Nagashima M, Morser J, Stern D, Schmidt AM (1999) RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 97(7):889–901CrossRef

Chavakis T, Bierhaus A, Al-Fakhri N, Schneider D, Witte S, Linn T, Nagashima M, Morser J, Arnold B, Preissner KT, Nawroth PP (2003) The pattern recognition receptor (RAGE) is a counterreceptor for leukocyte integrins: a novel pathway for inflammatory cell recruitment. J Exp Med 198(10):1507–1515CrossRef

Bierhaus A, Schiekofer S, Schwaninger M, Andrassy M, Humpert PM, Chen J, Hong M, Luther T, Henle T, Kloting I, Morcos M, Hofmann M, Tritschler H, Weigle B, Kasper M, Smith M, Perry G, Schmidt AM, Stern DM, Haring HU, Schleicher E, Nawroth PP (2001) Diabetes-associated sustained activation of the transcription factor nuclear factor-κB. Diabetes 50(12):2792–2808CrossRef

Kisugi R, Kouzuma T, Yamamoto T, Akizuki S, Miyamoto H, Someya Y, Yokoyama J, Abe I, Hirai N, Ohnishi A (2007) Structural and glycation site changes of albumin in diabetic patient with very high glycated albumin. Clin Chim Acta 382(1–2):59–64CrossRef

Unoki H, Bujo H, Yamagishi S, Takeuchi M, Imaizumi T, Saito Y (2007) Advanced glycation end products attenuate cellular insulin sensitivity by increasing the generation of intracellular reactive oxygen species in adipocytes. Diabetes Res Clin Pract 76(2):236–244CrossRef

Monden M, Koyama H, Otsuka Y, Morioka T, Mori K, Shoji T, Mima Y, Motoyama K, Fukumoto S, Shioi A, Emoto M, Yamamoto Y, Yamamoto H, Nishizawa Y, Kurajoh M, Yamamoto T, Inaba M (2013) Receptor for advanced glycation end products regulates adipocyte hypertrophy and insulin sensitivity in mice: involvement of Toll-like receptor 2. Diabetes 62(2):478–489CrossRef

Koyama H, Shoji T, Yokoyama H, Motoyama K, Mori K, Fukumoto S, Emoto M, Tamei H, Matsuki H, Sakurai S, Yamamoto Y, Yonekura H, Watanabe T, Yamamoto H, Nishizawa Y (2005) Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol 25(12):2587–2593CrossRef

10.

Basta G (2008) Receptor for advanced glycation endproducts and atherosclerosis: from basic mechanisms to clinical implications. Atherosclerosis 196(1):9–21CrossRef

11.

Choi KM, Yoo HJ, Kim HY, Lee KW, Seo JA, Kim SG, Kim NH, Choi DS, Baik SH (2009) Association between endogenous secretory RAGE, inflammatory markers and arterial stiffness. Int J Cardiol 132(1):96–101CrossRef

12.

Norata GD, Garlaschelli K, Grigore L, Tibolla G, Raselli S, Redaelli L, Buccianti G, Catapano AL (2009) Circulating soluble receptor for advanced glycation end products is inversely associated with body mass index and waist/hip ratio in the general population. Nutr Metab Cardiovasc Dis 19(2):129–134CrossRef

13.

Vazzana N, Santilli F, Cuccurullo C, Davi G (2009) Soluble forms of RAGE in internal medicine. Intern Emerg Med 4(5):389–401CrossRef

14.

ADA (2015) Standards of medical care in diabetes–2015: summary of revisions. Diabetes Care 38(Suppl):S4

15.

An P, Miljkovic I, Thyagarajan B, Kraja AT, Daw EW, Pankow JS, Selvin E, Kao WH, Maruthur NM, Nalls MA, Liu Y, Harris TB, Lee JH, Borecki IB, Christensen K, Eckfeldt JH, Mayeux R, Perls TT, Newman AB, Province MA (2014) Genome-wide association study identifies common loci influencing circulating glycated hemoglobin (HbA1c) levels in non-diabetic subjects: the Long Life Family Study (LLFS). Metabolism 63(4):461–468CrossRef

16.

Hudson BI, Dong C, Gardener H, Elkind MS, Wright CB, Goldberg R, Sacco RL, Rundek T (2014) Serum levels of soluble receptor for advanced glycation end-products and metabolic syndrome: the Northern Manhattan Study. Metabolism 63(9):1125–1130CrossRef

17.

Uribarri J, Cai W, Woodward M, Tripp E, Goldberg L, Pyzik R, Yee K, Tansman L, Chen X, Mani V, Fayad ZA, Vlassara H (2015) Elevated serum advanced glycation endproducts in obese indicate risk for the metabolic syndrome: a link between healthy and unhealthy obesity? J Clin Endocrinol Metab 100(5):1957–1966CrossRef

18.

Agarwal MM, Dhatt GS, Shah SM (2010) Gestational diabetes mellitus: simplifying the international association of diabetes and pregnancy diagnostic algorithm using fasting plasma glucose. Diabetes Care 33(9):2018–2020CrossRef

19.

Colhoun HM, Betteridge DJ, Durrington P, Hitman G, Neil A, Livingstone S, Charlton-Menys V, Bao W, Demicco DA, Preston GM, Deshmukh H, Tan K, Fuller JH (2011) Total soluble and endogenous secretory receptor for advanced glycation end products as predictive biomarkers of coronary heart disease risk in patients with type 2 diabetes: an analysis from the CARDS trial. Diabetes 60(9):2379–2385CrossRef

20.

Yamagishi S, Adachi H, Nakamura K, Matsui T, Jinnouchi Y, Takenaka K, Takeuchi M, Enomoto M, Furuki K, Hino A, Shigeto Y, Imaizumi T (2006) Positive association between serum levels of advanced glycation end products and the soluble form of receptor for advanced glycation end products in nondiabetic subjects. Metabolism 55(9):1227–1231CrossRef

21.

de Giorgis T, D’Adamo E, Giannini C, Chiavaroli V, Scarinci A, Verrotti A, Chiarelli F, Mohn A (2012) Could receptors for advanced glycation end products be considered cardiovascular risk markers in obese children? Antioxid Redox Signal 17(2):187–191CrossRef

22.

Selvin E, Halushka MK, Rawlings AM, Hoogeveen RC, Ballantyne CM, Coresh J, Astor BC (2013) sRAGE and risk of diabetes, cardiovascular disease, and death. Diabetes 62(6):2116–2121CrossRef

23.

Malavazos AE, Corsi MM, Ermetici F, Coman C, Sardanelli F, Rossi A, Morricone L, Ambrosi B (2007) Proinflammatory cytokines and cardiac abnormalities in uncomplicated obesity: relationship with abdominal fat deposition. Nutr Metab Cardiovasc Dis 17(4):294–302CrossRef

24.

Despres JP (2012) Body fat distribution and risk of cardiovascular disease: an update. Circulation 126(10):1301–1313CrossRef

25.

Rosito GA, Massaro JM, Hoffmann U, Ruberg FL, Mahabadi AA, Vasan RS, O’Donnell CJ, Fox CS (2008) Pericardial fat, visceral abdominal fat, cardiovascular disease risk factors, and vascular calcification in a community-based sample: the Framingham Heart Study. Circulation 117(5):605–613CrossRef

26.

Mahabadi AA, Reinsch N, Lehmann N, Altenbernd J, Kalsch H, Seibel RM, Erbel R, Mohlenkamp S (2010) Association of pericoronary fat volume with atherosclerotic plaque burden in the underlying coronary artery: a segment analysis. Atherosclerosis 211(1):195–199CrossRef

27.

Iacobellis G, Lonn E, Lamy A, Singh N, Sharma AM (2011) Epicardial fat thickness and coronary artery disease correlate independently of obesity. Int J Cardiol 146(3):452–454CrossRef

28.

Dozio E, Briganti S, Vianello E, Dogliotti G, Barassi A, Malavazos AE, Ermetici F, Morricone L, Sigruener A, Schmitz G, Corsi Romanelli MM (2015) Epicardial adipose tissue inflammation is related to vitamin D deficiency in patients affected by coronary artery disease. Nutr Metab Cardiovasc Dis 25(3):267–273CrossRef

29.

Dozio E, Dogliotti G, Malavazos AE, Bandera F, Cassetti G, Vianello E, Zelaschi R, Barassi A, Pellissero G, Solimene U, Morricone L, Sigruener A, Tarabin V, Schmitz G, Menicanti L, Corsi Romanelli MM (2012) IL-18 level in patients undergoing coronary artery bypass grafting surgery or valve replacement: which link with epicardial fat depot? Int J Immunopathol Pharmacol 25(4):1011–1020CrossRef

30.

Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28(7):412–419CrossRef

31.

Kahn HS (2005) The “lipid accumulation product” performs better than the body mass index for recognizing cardiovascular risk: a population-based comparison. BMC Cardiovasc Disord 5:26CrossRef

32.

Ceriello A, Colagiuri S (2008) International Diabetes Federation guideline for management of postmeal glucose: a review of recommendations. Diabet Med 25(10):1151–1156CrossRef

33.

Fluchter S, Haghi D, Dinter D, Heberlein W, Kuhl HP, Neff W, Sueselbeck T, Borggrefe M, Papavassiliu T (2007) Volumetric assessment of epicardial adipose tissue with cardiovascular magnetic resonance imaging. Obesity (Silver Spring) 15(4):870–878CrossRef

34.

Malavazos AE, Di Leo G, Secchi F, Lupo EN, Dogliotti G, Coman C, Morricone L, Corsi MM, Sardanelli F, Iacobellis G (2010) Relation of echocardiographic epicardial fat thickness and myocardial fat. Am J Cardiol 105(12):1831–1835CrossRef

35.

van der Kooy K, Seidell JC (1993) Techniques for the measurement of visceral fat: a practical guide. Int J Obes Relat Metab Disord 17(4):187–196

36.

Gaens KH, Stehouwer CD, Schalkwijk CG (2013) Advanced glycation endproducts and its receptor for advanced glycation endproducts in obesity. Curr Opin Lipidol 24(1):4–11CrossRef

37.

Gaens KH, Goossens GH, Niessen PM, van Greevenbroek MM, van der Kallen CJ, Niessen HW, Rensen SS, Buurman WA, Greve JW, Blaak EE, van Zandvoort MA, Bierhaus A, Stehouwer CD, Schalkwijk CG (2014) Nepsilon-(carboxymethyl)lysine-receptor for advanced glycation end product axis is a key modulator of obesity-induced dysregulation of adipokine expression and insulin resistance. Arterioscler Thromb Vasc Biol 34(6):1199–1208CrossRef

38.

Ojima A, Matsui T, Nakamura N, Higashimoto Y, Ueda S, Fukami K, Okuda S, Yamagishi S (2015) DNA aptamer raised against advanced glycation end products (AGEs) improves glycemic control and decreases adipocyte size in fructose-fed rats by suppressing AGE-RAGE axis. Horm Metab Res 47(4):253–258

39.

Dozio E, Vianello, E., Briganti, S., Lamont, J., Tacchini, L., Schmitz, G., Corsi Romanelli, M.M. (2016) Expression of the receptor for advanced glycation end products in epicardial fat: link with tissue thickness and local insulin resistance in coronary artery disease. J Diabetes Res (Article ID 2327341):1–8

40.

Sebekova K, Somoza V, Jarcuskova M, Heidland A, Podracka L (2009) Plasma advanced glycation end products are decreased in obese children compared with lean controls. Int J Pediatr Obes 4(2):112–118CrossRef

41.

He CT, Lee CH, Hsieh CH, Hsiao FC, Kuo P, Chu NF, Hung YJ (2014) Soluble form of receptor for advanced glycation end products is associated with obesity and metabolic syndrome in adolescents. Int J Endocrinol 2014:657607

42.

Momma H, Niu K, Kobayashi Y, Huang C, Chujo M, Otomo A, Tadaura H, Miyata T, Nagatomi R (2014) Higher serum soluble receptor for advanced glycation end product levels and lower prevalence of metabolic syndrome among Japanese adult men: a cross-sectional study. Diabetol Metab Syndr 6(1):33CrossRef

43.

Davidovich D, Gastaldelli A, Sicari R (2013) Imaging cardiac fat. Eur Heart J Cardiovasc Imaging 14(7):625–630CrossRef

44.

Talman AH, Psaltis PJ, Cameron JD, Meredith IT, Seneviratne SK, Wong DT (2014) Epicardial adipose tissue: far more than a fat depot. Cardiovasc Diagn Ther 4(6):416–429

45.

Saremi F, Mekhail S, Sefidbakht S, Thonar B, Malik S, Sarlaty T (2011) Quantification of epicardial adipose tissue: correlation of surface area and volume measurements. Acad Radiol 18(8):977–983CrossRef

46.

Bertaso AG, Bertol D, Duncan BB, Foppa M (2013) Epicardial fat: definition, measurements and systematic review of main outcomes. Arq Bras Cardiol 101(1):e18–e28

47.

Maislin G, Ahmed MM, Gooneratne N, Thorne-Fitzgerald M, Kim C, Teff K, Arnardottir ES, Benediktsdottir B, Einarsdottir H, Juliusson S, Pack AI, Gislason T, Schwab RJ (2012) Single slice vs. volumetric MR assessment of visceral adipose tissue: reliability and validity among the overweight and obese. Obesity (Silver Spring) 20(10):2124–2132CrossRef

Title: Relationship between soluble receptor for advanced glycation end products (sRAGE), body composition and fat distribution in healthy women
Authors: Elena Dozio
Silvia Briganti
Alessandra Delnevo
Elena Vianello
Federica Ermetici
Francesco Secchi
Francesco Sardanelli
Lelio Morricone
Alexis E. Malavazos
Massimiliano M. Corsi Romanelli
Publication date: 01-12-2017
Publisher: Springer Berlin Heidelberg
Published in: European Journal of Nutrition / Issue 8/2017
Print ISSN: 1436-6207
Electronic ISSN: 1436-6215
DOI: https://doi.org/10.1007/s00394-016-1291-0

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Relationship between soluble receptor for advanced glycation end products (sRAGE), body composition and fat distribution in healthy women

Abstract

Purpose

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 8/2017

Main biomarkers associated with age-related plasma zinc decrease and copper/zinc ratio in healthy elderly from ZincAge study

Age and time trends in eating frequency and duration of nightly fasting of German children and adolescents

Amino acids regulate mTOR pathway and milk protein synthesis in a mouse mammary epithelial cell line is partly mediated by T1R1/T1R3

Modulation of postprandial lipaemia by a single meal containing a commonly consumed interesterified palmitic acid-rich fat blend compared to a non-interesterified equivalent

Trimethylamine-N-oxide and its biological variations in vegetarians

Lutein attenuates oxidative stress markers and ameliorates glucose homeostasis through polyol pathway in heart and kidney of STZ-induced hyperglycemic rat model

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page